[LXRX] YoY Quarter Result on 30-Jun-2016 [#Q2]

Stock

[LXRX] Lexicon Pharmaceuticals, Inc.

Announcement Date

04-Aug-2016

Financial Year

2016

Quarter

30-Jun-2016 [#Q2]

Profit Trend

QoQ- -9.26%

YoY- -35.76%

Quarter Report

Filling Detail

Form 10-Q

LXRX's Result

LXRX's Financial Summary

View:

Show?

YoY %

Horiz. %

	30/06/19	30/06/18	30/06/17	30/06/16	30/06/15	30/06/14	30/06/13	CAGR
Quarter Result
Revenue	9,682	13,753	12,053	20,089	376	676	214	88.71%
YoY %	-29.60%	14.10%	-40.00%	5,242.82%	-44.38%	215.89%	-	-
Horiz. %	4,524.30%	6,426.64%	5,632.24%	9,387.38%	175.70%	315.89%	100.00%	-
PBT	-23,018	-34,706	-35,059	-38,112	-28,074	-26,028	-29,080	-3.81%
YoY %	33.68%	1.01%	8.01%	-35.76%	-7.86%	10.50%	-	-
Horiz. %	79.15%	119.35%	120.56%	131.06%	96.54%	89.50%	100.00%	-
Tax	-219	6,097	2,062	1,638	1,655	435	-333	-6.74%
YoY %	-103.59%	195.68%	25.89%	-1.03%	280.46%	230.63%	-	-
Horiz. %	65.77%	-1,830.93%	-619.22%	-491.89%	-497.00%	-130.63%	100.00%	-
NP	-23,018	-34,706	-35,059	-38,112	-28,074	-26,028	-29,080	-3.81%
YoY %	33.68%	1.01%	8.01%	-35.76%	-7.86%	10.50%	-	-
Horiz. %	79.15%	119.35%	120.56%	131.06%	96.54%	89.50%	100.00%	-
Tax Rate	-	-	-	-	-	-	-	-
YoY %	-	-	-	-	-	-	-	-
Horiz. %	-	-	-	-	-	-	-	-
Total Cost	32,700	48,459	47,112	58,201	28,450	26,704	29,294	1.84%
YoY %	-32.52%	2.86%	-19.05%	104.57%	6.54%	-8.84%	-	-
Horiz. %	111.63%	165.42%	160.82%	198.68%	97.12%	91.16%	100.00%	-

	30/06/19	30/06/18	30/06/17	30/06/16	30/06/15	30/06/14	30/06/13	CAGR
Ratio Analysis
NP Margin	-237.74	-252.35	-290.87	-189.72	-7,466.49	-3,850.30	-13,588.79	-49.03%
YoY %	5.79%	13.24%	-53.32%	97.46%	-93.92%	71.67%	-	-
Horiz. %	1.75%	1.86%	2.14%	1.40%	54.95%	28.33%	100.00%	-

	30/06/19	30/06/18	30/06/17	30/06/16	30/06/15	30/06/14	30/06/13	CAGR
Per Share
EPS	-0.22	-0.33	-0.33	-0.37	-0.27	-0.35	-0.40	-9.47%
YoY %	33.33%	0.00%	10.81%	-37.04%	22.86%	12.50%	-	-
Horiz. %	55.00%	82.50%	82.50%	92.50%	67.50%	87.50%	100.00%	-
EPS Diluted	-0.22	-0.33	-0.33	-0.37	-0.27	-0.35	-0.40	-9.47%
YoY %	33.33%	0.00%	10.81%	-37.04%	22.86%	12.50%	-	-
Horiz. %	55.00%	82.50%	82.50%	92.50%	67.50%	87.50%	100.00%	-

PBT = Profit before Tax, NP = Net Profit, NP Margin = Net Profit Margin, EPS = Earning Per Share, EPS Diluted = Earning Per Share Diluted.

NP Margin, QoQ ⃤ & YoY ⃤ figures in Percentage; EPS & EPS Diluted figures in Cent.

All figures in '000 unless specified.

Latest Videos

MQ Market Updates - 5 November 2024

MQ Trader

Apps

MQ Chat

Send individual or group chats with anyone on i3investor

MQ Trader

Earn MQ Points while trading with MQ Trader

MQ Affiliate

Earn side income from Affiliate Program

MQdemy

Online learning and teaching marketplace

Hot Stocks Today >

BABA

Alibaba Group Holding Limited

1000

META

Meta Platforms, Inc.

800

PLTR

Palantir Technologies Inc.

750

AGN

500

VNR

500

TSM

Taiwan Semiconductor Manufacturing Company Limited

500

AAPL

Apple Inc.

500

MSFT

Microsoft Corporation

300

OUT

Outfront Media Inc.

250

VYM

Vanguard High Dividend Yield Index Fund

250

Daily Stocks

LMDX

0.016

-0.018

120,553,903

LILM

0.209

-0.334

112,784,715

NVDA

762.00

-84.71

85,558,284

LUV

28.76

-5.02

40,709,885

MBIO

0.561

-0.29

37,521,166

NEM

49.25

-8.49

36,687,917

MRK

115.25

-12.53

34,208,192

PHUN

8.48

-5.66

33,555,042

MNTS

0.634

-0.426

31,360,930

88.58

-7.66

25,569,497

More active Stocks

NVSCX

33.26

+0.24

PRB

24.54

+0.04

4,003

PHAS

0.07

0.00

8,562,718

KNBE

24.89

0.00

5,727,439

RIDE

2.20

0.00

1,328,882

PCPC-WT

0.161

0.00

1,184,570

KALWW

0.005

0.00

959,657

PNACR

0.54

0.00

549,213

PPR

4.67

0.00

546,256

ASZ-WT

0.08

0.00

498,419

More gainer Stocks

MELI

1,629.32

-188.66

1,851,535

MPWR

759.30

-160.51

2,985,808

MSTR

1,309.00

-138.99

2,237,917

MKL

1,395.13

-102.30

318,280

NOW

643.29

-87.83

5,025,012

NVDA

762.00

-84.71

85,558,284

MEDP

357.30

-79.88

1,004,401

MDB

236.06

-73.94

10,812,930

MCK

547.51

-70.00

4,067,959

OLED

172.28

-40.39

1,254,445

More loser Stocks

Books Review >

Ride The Bull Short The Bear

CS Tan

4.9 / 5.0

This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....

Read More